ערך בספרים למניה: iCAD Corp (ICAD)
iCAD, Inc. (ICAD) generates revenue through the implementation of ProFound AI for breast cancer diagnostics and therapy. The scalability of the cloud-based SaaS service enables clinics to integrate without capital expenditures. The net asset value per share visualizes this efficiency, where 1.14 determines the latest valuation metric. Stringent FDA standards and B2B software integration ensure steady license growth and market protection.
פילוחי נתונים אנליטיים מרוכזים עבור iCAD Inc. (ICAD)
Book value per share reflects the portion of equity attributable to a single security and serves as an indicator of the business's intrinsic value regardless of market fluctuations. By analyzing the book value per share trend, an investor assesses the financial stability of iCAD, Inc. (ICAD) amid the slow adoption of AI systems in medicine and the transition to a subscription model to protect margins.